DS
TOVX icon

DRW Securities’s Theriva Biologics TOVX Stock Holding History

DRW Securities’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,745
Closed -$8.78K – 1715
2025
Q4 		$8.78K Buy
+41,745
New +$12.3K ﹤0.01% 1181

Other funds holding TOVX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DRW Securities's TOVX Position: Q1 2026 in Review

DRW Securities sold out of Theriva Biologics (TOVX) in Q1 2026, closing a stake of 41,745 shares — an estimated $8.78K sold.

DRW Securities first reported a position in TOVX in Q4 2025 and held it in 1 quarter. The position peaked at $8.78K in Q4 2025. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

  • DRW Securities reported no remaining Theriva Biologics position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 41,745 Theriva Biologics shares in Q1 2026, an estimated $8.78K.
  • DRW Securities first reported a position in Theriva Biologics in Q4 2025 and held it in 1 quarter.
  • DRW Securities's Theriva Biologics position peaked at $8.78K in Q4 2025.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.